Clinical trials: Diabetic Nephropathies
Healthy
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
The goals of this study are to evaluate the safety and tolerability of multiple ascending doses of PF-04634817 administered orally to healthy adult subjects.
- Trial name
- NCT01140672
- Testing
- PF-04634817
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- NCT00913393
- Testing
- FG-3019
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kyntra Bio
Chronic Glomerulonephritis, Diabetic Nephropathy
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg, 20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12.
- Trial name
- NCT00914524
- Testing
- olmesartan medoxomil
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetic Chronic Kidney Disease
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
A phase 2b, placebo-controlled, randomized, double-blind, multi-center study of GCS-100 in patients with chronic kidney disease caused by diabetes.
- Trial name
- NCT02312050
- Testing
- GCS-100
- Where
- 8 sites in United States
- Volunteers
- 375 people
- Sponsor
- La Jolla Pharmaceutical Company
Diabetic Nephropathy
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
- Trial name
- NCT00097955
- Testing
- aliskiren
- Where
- 12 sites in United States, Canada and 10 more
- Volunteers
- 496 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.
- Trial name
- NCT02251067
- Testing
- VPI-2690B low dose, VPI-2690B medium dose, VPI-2690B high dose
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 165 people
- Sponsor
- Vascular Pharmaceuticals, Inc.
Diabetic Nephropathy
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
This Phase 2A study is an adaptive design pilot study investigating the efficacy and safety of daily Acthar administration in diabetic patients with nephropathy and proteinuria.
- Trial name
- NCT01601236
- Testing
- Repository Corticotropin Injection
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mallinckrodt
Diabetic Kidney Disease (DKD)
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus…
- Trial name
- NCT06866158
- Testing
- Dendritic cell immunotherapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- PT. JES Kasih Nusantara Sejahterah
Diabetic Nephropathy
Effects of PH3 in Diabetic Nephropathy
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy.
- Trial name
- PH3 (NCT01068041)
- Testing
- PH3
- Where
- 3 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- PhytoHealth Corporation
Kidney Disease
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy.
- Trial name
- BREAKOUT (NCT05709444)
- Testing
- Bremelanotide, RAAS inhibition therapy
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Palatin Technologies, Inc
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Albuminuria, Diabetic Nephropathy
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL784 when given daily to patients with albuminuria due to diabetic nephropathy.
- Trial name
- NCT00312780
- Testing
- XL784
- Where
- 45 sites in United States
- Volunteers
- 125 people
- Sponsor
- Symphony Evolution, Inc.
Chronic Kidney Disease
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function.
- Trial name
- NCT04736628
- Testing
- Avenciguat
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Diabetic Kidney Disease
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)
- Trial name
- NCT06006689
- Testing
- Low dose Qishen Yiqi Dripping Pills 3 bags, High dose Qishen Yiqi Dripping Pills 3 bags
- Where
- 16 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Nephropathy, Diabetic
- Trial name
- NCT04534439
- Testing
- APX-115
- Where
- 16 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 140 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetic Nephropathies, Hypertension
Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day.
- Trial name
- CARDINAL (NCT00713011)
- Testing
- Adalat XL, Tiazac XC
- Sponsor
- Bayer